$TSHA

Taysha Gene Therapies, Inc.

Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is an investigational gene therapy for Rett syndrome, designed as a one-time intrathecal treatment for females with the disorder. Taysha is evaluating TSHA-102 in the REVEAL clinical trials and the ASPIRE safety-focused study. It also has early-stage programs TSHA-113 for tauopathies and TSHA-114 for Fragile X syndrome. The company discontinued evaluation of TSHA-106 for Angelman syndrome in 2025. Taysha’s work centers on discovering, developing and commercializing gene therapies. Its pipeline targets central nervous system diseases, and its programs are at different stages of development. Taysha is headquartered in Dallas, Texas.

2
1
4

No SEC Form 4 filings for $TSHA in the last 30 days.

See all $TSHA insider activity →
Med

Taysha Gene Therapies Reports Q3 2026 Results; Cash of $422.8 Million

Taysha Gene Therapies reported a Q3 2026 net loss of $39.1M, up from $32.7M a year earlier, with zero revenue. R&D and G&A expenses increased. Cash reserves were $422.8M. TSHA-102 trials for Rett syndrome are ongoing, with interim data and FDA feedback expected in 2027. Cash is expected to last into 2H 2028.

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submis

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (TSHA) granted 384,000 RSUs and options for 92,400 shares to four new employees under Nasdaq Rule 5635(c)(4). RSUs vest over four years, and the stock options have a $4.74 exercise price, vesting over four years with a 10-year term. TSHA focuses on AAV-based gene therapies for severe CNS diseases, with its lead program TSHA-102 targeting Rett syndrome.

TSHA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning TSHA (Taysha Gene Therapies, Inc.). Coverage has skewed bearish: 2 bullish, 1 neutral, and 4 bearish.

Recent TSHA coverage spans earnings, corporate actions and financial news.

What's driving TSHA

AlphAI scores every news story that mentions TSHA with an AI model for sentiment and relevance, and aggregates insider trades from Taysha Gene Therapies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TSHA

Score
$TSHAMedEarnings

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submis

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (TSHA) granted 384,000 RSUs and options for 92,400 shares to four new employees under Nasdaq Rule 5635(c)(4). RSUs vest over four years, and the stock options have a $4.74 exercise price, vesting over four years with a 10-year term. TSHA focuses on AAV-based gene therapies for severe CNS diseases, with its lead program TSHA-102 targeting Rett syndrome.

These 3 Risky Stocks Could Be Sitting on 100% Upside

Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.

$TSHAMedAI 8/10

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

Taysha Gene Therapies (TSHA) reported Q2 2026 earnings, with a net loss of $46.6M, up from $26.9M in the prior year. R&D expenses rose to $38.6M, and cash reserves totaled $455.4M. The company completed dosing in REVEAL and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with 100% of Part A patients meeting responder status. Management expects regulatory discussions in H1 2027 and extended cash runway into H2 2028.

$TSHAMedEarnings

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

Taysha Gene Therapies (NASDAQ:TSHA) priced an underwritten public offering of 32.5M shares at $6 each on June 24, plus prepaid warrants for 833,333 shares at $5.999 per warrant. The company expects about $200M gross proceeds and a 30-day option for up to 5M more shares. Bank of America raised its TSHA target to $10 from $9 and reiterated Buy after Part A REVEAL Rett syndrome study updates.

Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run

Taysha Gene Therapies said its R&D chief sold about $1.2 million of stock under a 10b5-1 plan, after a 149% share run. The executive still holds 936,410 shares. The company also reaffirmed FDA alignment for TSHA-102’s BLA pathway, citing REVEAL trial dosing completion of 17 patients and early durable results, with $276.6 million cash into 2028.

Related tickers